Understanding the new Apifiny test for prostate cancer risk


We have just come across the first patient we know of to be given an Apifiny test for risk of prostate cancer. He had an Apifiny score of 89 — but quite what that might mean seems to be a little unclear (as is why this particular patient was given the test, since he is 81 years of age but, as yet, we don’t know his PSA level).

To quote the information being distributed by Armune Biosciences, the developer of the Apifiny test, this test

may be used in men who have an elevated PSA (> 2.5 ng/ml) and are considering a prostate biopsy.

If the Apifiny score is 59 or less, then the patient is supposedly at “lower” risk for prostate cancer and if the score is 60 to 100 then the patient is at “higher” risk. The implication is that a man with an Apinify test score of < 60 probably doesn’t need a biopsy (if there are no other indicators of risk). Of course the unanswered question is whether a man at higher risk is also at higher risk for prostate cancer of any type (indolent disease included) or whether the Apifiny score tells us anything at all about risk for clinically significant disease.

The information available from Armune at this time is limited. We were able to find the following on or via the company’s web site:

We want to be very clear that the Apifiny test may well be very useful. It was developed in association with Arul Chinnaiyan and others at the University of Michigan who most certainly know what they are doing. However, if the Apifiny test really is going to have practical, routine value in the diagnosis of prostate cancer, then (in our humble opinions) both doctors and their patients need some better guidance about the implications of the results of the test!

3 Responses

  1. In Armune’s literature, they tell us that at a cut point of 59, the positive predictive value is 0.34 and the negative predictive value is 0.88. This means that two-thirds of men who are sent to a biopsy on the basis of this test will turn out to be negative for prostate cancer. On the other hand, only 12% of the men who are told by the test that they do not have prostate cancer, will indeed be found to have it if they have a biopsy anyway. It is really no better than %free PSA at a cut point of 10%, but not as good as phi or PCA3. For a cost of over $300, this is not a very good test.

  2. Thanks Allen … I didn’t find that piece of physician-directed literature in my quick review.

  3. I recently scored a 99 on the Apifiny test. Informed a couple of days ago that the biopsy was negative for cancer. One data point, for what it’s worth.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: